CAS 133524-69-3: Benzenepropanoic acid, β-amino-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-

N-Desboc docetaxel-d5 is a deuterated analog of the chemotherapy drug docetaxel, which is derived from the diterpenoid taxane with a substitution at isotopic positions. This compound is synthesized to enhance the stability and traceability of docetaxel in biological systems during pharmacokinetic and metabolic studies. Its mode of action involves the inhibition of microtubule depolymerization, thus disrupting cell division and leading to apoptosis in rapidly dividing cancer cells. Applications of N-Desboc docetaxel-d5 are primarily within the realm of drug metabolism and pharmacokinetic research. By incorporating deuterium atoms, researchers can more accurately track and quantify the distribution and breakdown of the docetaxel molecule in vivo and in vitro. Such studies are crucial in understanding the pharmacological profile and metabolic pathways of docetaxel, facilitating the optimization of dosing regimens and the development of novel therapeutic strategies. Its utilization is a testament to the innovative approaches in drug development and cancer research, pushing the boundaries of precision medicine.

Applications N-DesBoc Docetaxel is an impurity in the synthesis of Docetaxel (D494420), a semisynthetic derivative of Paclitaxel. An antimitotic agent that promotes the assembly of micro-tubules and inhibits their de-polymerization to free tubulin. An antine oplastic. References Ringel, I., et al.: J. Natl. Cancer Inst., 83, 288 (1991), Extra, J.-M., et al.: Cancer Res., 53, 1037 (1993)